Tumor purity coexpressed genes related to immune microenvironment and clinical outcomes of lung adenocarcinoma
Journal of Oncology — Bai M, et al. | June 15, 2021
Since there exists an important role of tumor purity in the immune response to lung cancer, and there is lack of clarity about the biological processes associated with the purity of lung cancer tumors, thus, researchers herein ascertained tumor purity in 486 lung carcinoma tissues from TCGA(The Cancer Genome Atlas)-LUAD FPKM by employing the “estimate” R package. Using TCGA single nucleotide polymorphism data, lung carcinoma tumor mutation burden was computed. Experts determined a lung cancer tumor purity correlated coexpression network. CD4, CD53, EVI2B, PLEK, and SASH3 were the five tumor purity coexpressed genes that were negatively correlated with tumor purity. Since the factors in the coexpression network frequently involve in similar biological processes, CD4, CD53, EVI2B, PLEK, and SASH3 were shown to be most associated with positive regulation of cytokine production and interleukin−2 production via functional enrichment. A clinical phenotype analysis revealed that these five factors can be employed as independent prognostic risk factors. Overall, findings demonstrate important clinical, genomic, as well as biological significance of tumor purity-related coexpression factors in the tumor microenvironment in lung cancer. Not only tumor purity phenotypes can be classified with the help of these coexpression factors (SASH3 and CD53), but also these can be used to predict clinical results.
Your browser is currently blocking ads. We depend on ad sponsorships in order to keep this site free to the healthcare provider community. Help us keep this site free by turning off your ad blocker.
Turn Off Ad Blocker
We have detected that you are currently blocking ads. We kindly ask that you enable ads when visiting our site. We depend on ad sponsorships in order to keep this site free to the healthcare provider community.